Machine signal
Active cluster sell — 6 distinct insiders, $7.9M, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 207.81 USD (+45%) · consensus 4.57/5 · 24 buy · 4 hold · 0 sell
Ownershipinsiders 1.06% · institutions 102.82% · short 6.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for NEUROCRINE BIOSCIENCES INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
108 buys1,242 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Cooke Julie | Other | $302.4K | SEC |
| Delaet Ingrid | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ABERNETHY MATT | Other | $423.2K | SEC |
| ABERNETHY MATT | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lippoldt Darin | Other | $377.9K | SEC |
| Gano Kyle | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lippoldt Darin | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Keswani Sanjay Chandru | Other | $329.9K | SEC |
| Boyer David W. | Other | $302.4K | SEC |
| Gano Kyle | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GORMAN KEVIN CHARLES | Other | $1.2M | SEC |
| Delaet Ingrid | Other | $377.9K | SEC |
| BENEVICH ERIC | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gano Kyle | Other | $529K | SEC |
| Boyer David W. | Sell | $130.1K | SEC |
| Onyia Jude | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boyer David W. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cooke Julie | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BENEVICH ERIC | Other | $529K | SEC |
| Onyia Jude | Other | $302.4K | SEC |
| ABERNETHY MATT | Sell | $363.3K | SEC |
| Gano Kyle | Other | $155.3K | SEC |
| Keswani Sanjay Chandru | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GORMAN KEVIN CHARLES | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BENEVICH ERIC | Sell | $333K | SEC |